Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells ; volume:1 ; number:1 ; day:7 ; month:11 ; year:2013 ; pages:1 ; date:11.2013
Journal for ImmunoTherapy of Cancer ; 1, Heft 1 (7.11.2013), 1, 11.2013
- Creator
-
Mannioui, Cécile Schiffer
- Contributor
-
Lemaire, Laëtitia
Poirot, Laurent
Gouble, Agnes
Arnould, Sylvain
Galetto, Roman
Smith, Julianne
Scharenberg, Andrew
SpringerLink (Online service)
- DOI
-
10.1186/2051-1426-1-S1-P34
- URN
-
urn:nbn:de:1111-2016072654646
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mannioui, Cécile Schiffer
- Lemaire, Laëtitia
- Poirot, Laurent
- Gouble, Agnes
- Arnould, Sylvain
- Galetto, Roman
- Smith, Julianne
- Scharenberg, Andrew
- SpringerLink (Online service)
Other Objects (12)
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
Recent updates on allogeneic CAR-T cells in hematological malignancies
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
CD3/CD19 Depletion for T-cell Reduction of Allogeneic Transplants: Mostly Efficient, but not Robust
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies
Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell grafts
A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
Recent updates on allogeneic CAR-T cells in hematological malignancies
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
CD3/CD19 Depletion for T-cell Reduction of Allogeneic Transplants: Mostly Efficient, but not Robust
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies
Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell grafts
A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
Recent updates on allogeneic CAR-T cells in hematological malignancies
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
CD3/CD19 Depletion for T-cell Reduction of Allogeneic Transplants: Mostly Efficient, but not Robust
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies
Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell grafts